Mekinist is approved by the Food and Drug Administration (FDA) to treat specific types of lung cancer, melanoma, anaplastic thyroid cancer, and solid tumors in adults. Mekinist is also approved to ...

Tafinlar and Mekinist are also indicated in more than 35 countries worldwide, including the US and EU, as single agents to treat patients with unresectable or metastatic melanoma with a BRAF V600 ...

The FDA has approved Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation who require systemic therapy.

Mekinist is a mitogen-activated extracellular kinase (MEK) inhibitor that blocks the activation of the protein-kinase B-raf (BRAF) pathway, thereby causing decreased cellular proliferation, cell ...

NEW YORK — The Food and Drug Administration recently approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (i.e ...

Basel, September 1, 2015 - Novartis today announced that the European Commission has approved the combination of Tafinlar ® (dabrafenib) and Mekinist ® (trametinib) for the treatment of adult ...

Tafinlar + Mekinist remains an effective treatment option based on previously reported large, Phase III clinical trials1,2 Spartalizumab development program continues, investigating the ...

Of patients who achieved a complete response with Tafinlar + Mekinist, 19% (n=109) had five-year PFS and overall survival rates of 49% and 71%, respectively, compared with 19% and 34% in the ...

Basel, October 8, 2016 - Novartis today announced data from the Phase III COMBI-v study demonstrating an overall survival (OS) and a progression-free survival benefit for patients with BRAF V600 ...

RFS was improved with Tafinlar/Mekinist across all subgroups. Hazard ratios across all subgroups ranged from 0.33 to 0.55 in favor of Tafinlar and Mekinist versus placebo. Early data for overall ...

DORVAL, QC, Dec. 16, 2019 /CNW/ - Novartis is pleased to announce that British Columbia will now fund the combination of Tafinlar ® +Mekinist ® (dabrafenib + trametinib) for adjuvant treatment ...

The European Medicines Agency (EMA) has approved the MEK-inhibitor trametinib (Mekinist, GlaxoSmithKline) for the treatment of melanoma, following on from the positive opinion the product received ...